Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Account Payables: 2009-2024

Historic Change in Account Payables for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$72000.0.

  • OptimizeRx's Change in Account Payables rose 12444.44% to $55000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 326000.0%. This contributed to the annual value of -$72000.0 for FY2024, which is 9454.55% up from last year.
  • Latest data reveals that OptimizeRx reported Change in Account Payables of -$72000.0 as of FY2024, which was up 9454.55% from -$1.3 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Change in Account Payables ranged from a high of $943171.0 in FY2022 and a low of -$1.3 million during FY2023
  • Moreover, its 5-year median value for Change in Account Payables was -$11442.0 (2021), whereas its average is -$67003.2.
  • In the last 5 years, OptimizeRx's Change in Account Payables skyrocketed by 834306.07% in 2022 and then tumbled by 23995.34% in 2023.
  • OptimizeRx's Change in Account Payables (Annual) stood at $125255.0 in 2020, then tumbled by 109.13% to -$11442.0 in 2021, then soared by 8343.06% to $943171.0 in 2022, then crashed by 239.95% to -$1.3 million in 2023, then skyrocketed by 94.55% to -$72000.0 in 2024.
  • Its Change in Account Payables stands at -$72000.0 for FY2024, versus -$1.3 million for FY2023 and $943171.0 for FY2022.